Last Updated:
Sunday, January 23, 2022
3:27 PM
USA
CytoDyn
CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications based on Leronlimab (PRO 140).
Stock Quote
CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications based on Leronlimab (PRO 140).
Newsroom
May 5, 2020
Ajinomoto to supply COVID-19 treatment for CytoDyn
May 4, 2020
CytoDyn expects to fully enroll its trials to treat coronavirus patients ...
May 4, 2020
BRIEF-Cytodyn Says 49 COVID-19 Patients Have Enrolled For ...
April 30, 2020
Close to 50 Patients Treated with Leronlimab for COVID-19, Many ...
April 28, 2020
CytoDyn says leronlimab yielded positive data in Covid-19 patients
April 16, 2020
CytoDyn begins leronlimab treatment in coronavirus trial
April 15, 2020
CytoDyn treats first patient in its Phase 2b/3 coronavirus trial along ...
April 14, 2020
CytoDyn sees 'strong results' from leronlimab-treated coronavirus ...
April 13, 2020
CytoDyn Inc says five coronavirus (COVID-19) patients able to go off ...
April 9, 2020
CytoDyn's Leronlimab Shows Positive Responses In COVID-19 ...
Page
1
Page
2
Page
3
Stock Quote
Vaccine
Treatment
Testing
Stats
Infographics
Menu
Vaccine
Treatment
Testing
Stats
Infographics
